3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
101
Neoplasms, Plasma Cell
12
Recurrence
9
Lymphoma
8
Immunoglobulin Light-chain Amyloidosis
7
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
5
Neoplasms
5
Leukemia, Myeloid, Acute
5
Lymphoma, Mantle-Cell
4
Waldenstrom Macroglobulinemia
3
Paraproteinemias
3
Hematologic Neoplasms
3
Amyloidosis
3
Renal Insufficiency
2
Myelodysplastic Syndromes
2
Lymphoproliferative Disorders
2
Lymphoma, T-Cell
2
Burkitt Lymphoma
2
beta-Thalassemia
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Triple Negative Breast Neoplasms
1
Thalassemia
1
Sarcoma, Myeloid
1
Prostatic Neoplasms
1
Plasmacytoma
1
Plasmablastic Lymphoma
1
Peripheral Nervous System Diseases
1
Interventions
Nivolumab
3
capivasertib
2
Gemcitabine
2
Cisplatin
2
tivozanib
1
regorafenib
1
niraparib
1
neratinib
1
lutetium Lu 177 dotatate
1
fludarabine phosphate
1
fludarabine
1
encorafenib
1
durvalumab
1
copanlisib
1
cemiplimab
1
axicabtagene ciloleucel
1
avasopasem manganese
1
Valproic Acid
1
Thioctic Acid
1
Taxes
1
Receptors, Interleukin-6
1
Radiosurgery
1
RNA-Seq
1
Pemetrexed
1
Paclitaxel
1
Oxaliplatin
1
Multiparametric Magnetic Resonance Imaging
1
Leucovorin
1
Lenalidomide
1
Interleukin 1 Receptor Antagonist Protein
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Disease Progression
×
Bortezomib
×
1 year
×
Clear all
NCT01191060
2026-04-06
IFM/DFCI2009
University Hospital, Toulouse
Phase 3
Completed
700 enrolled